A Phase 1 interventional study of Apremilast Tablet and Apremilast Oral Suspension in Healthy Volunteers, sponsored by Amgen. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-05.
Sponsored by Amgen · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess how much of apremilast is found in the blood unchanged when administered as an oral suspension compared to when it is administered as a tablet formulation. The effect of food on apremilast oral suspension will also be evaluated. In addition, information on the safety and tolerability of apremilast will be obtained.
This is a phase 1, open-label, randomized, three-period, six-sequence crossover study in healthy subjects. The study will consist of a screening phase, baseline (Day -1), three study periods, and a follow-up phone call. Each study period will be four days in duration (Day 1 through Day 4) followed by a five-day washout between doses.
Eligible participants will be admitted into the study center on Day -1 of study Period 1 for baseline measurements. During each study period, participants will receive a single 30 mg oral dose of apremilast on Day 1 according to the assigned treatment sequence. Participants will be confined at the study center from Day 1 of study Period 1 through Day 4 of study Period 3, including the 5 day washout between doses. All participants will be discharged from the study center on Day 4 of study Period 3 following completion of required study procedures. A follow-up phone call will occur approximately four days after the discharge from the study center.
The study will be conducted in compliance with International Conference on Harmonisation (ICH) Good Clinical Practices (GCPs).
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must satisfy ALL of the following criteria to be eligible for enrollment into the study:
Requirements:
All FCBP must have a negative pregnancy test at Visits 1 and 2. All FCBP subjects who engage in activity in which conception is possible must use one of the approved contraceptive options described below:
Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom (latex condom or non-latex condom NOT made out of natural [animal] membrane [for example, polyurethane]); PLUS one of the following additional barrier methods: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (latex or non-latex condoms NOT made out of natural [animal] membrane [for example, polyurethane]) while on product (IP) and for at least 28 days after the last dose of IP.
Exclusion Criteria:
The presence of ANY of the following will exclude any healthy subject from enrollment into the study:
Known to have hepatitis, or known to be a carrier of the surface antigen (HBsAg), or antibody (HCV Ab), or have a positive result to the test for HBsAg, HCV Ab, or (HIV) antibodies at Screening.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single oral dose of 30 mg apremilast tablet after an overnight fast.
Drug: Apremilast Tablet
A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.
Drug: Apremilast Oral Suspension
A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.
Drug: Apremilast Oral Suspension
30 mg tablet
Also known as: Otzela, CC-10004
30 mg oral suspension
Also known as: Otzela, CC-10004
Maximum Observed Plasma Concentration (Cmax) of Apremilast
Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.
Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-t) for Apremilast
Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay. AUC from time zero to the last measured time point was calculated by the linear trapezoidal method.
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.
Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-∞) for Apremilast
Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay. AUC from time zero to infinity was calculated as (AUC0-t + Ct/λz), where Ct is the last quantifiable concentration, and λz is the apparent terminal rate constant.
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.
Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast
Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.
Terminal Elimination Half-life (T1/2) of Apremilast
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.
Apparent Clearance of Apremilast From Plasma After Extravascular Administration (CL/F)
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.
Apparent Volume of Distribution of Apremilast During the Terminal Phase (Vz/F)
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.
Lag Time (Tlag) of Apremilast
Lag time is the delay between the time of administration and start of absorption.
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.
Relative Bioavailability (F) of Apremilast Oral Suspension Formulation
Relative bioavailability of the oral suspension formulation compared to the tablet formulation, calculated as (AUC0-∞/Dose\[oral suspension\]) / (AUC0-∞/Dose\[tablet\]) \* 100%.
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.
Number of Participants With Treatment-emergent Adverse Events
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. A treatment-emergent AE (TEAE) was defined as any AE that occurred after dosing of the study drug. A serious adverse event (SAE) is any AE occurring at any dose that: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity; * Was a congenital anomaly/birth defect; * Constituted an important medical event.
Time frame: From first dose of study drug in treatment period 1 to 8 days after the last dose; up to 18 days.
Participants were enrolled at a single site in the United States. The study consisted of three treatment periods separated by a 5-day washout period.
| Milestone | Sequence 1: Treatments ACB | Sequence 2: Treatments CBA | Sequence 3: Treatments BAC | Sequence 4: Treatments ABC | Sequence 5: Treatments CAB | Sequence 6: Treatments BCA |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 6 | 6 | 6 | 6 |
| Completed | 5 | 5 | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.
| ng/mL | Treatment A: Apremilast 30 mg Tablet - Fasted | Treatment B: Apremilast 30 mg Oral Suspension - Fasted | Treatment C: Apremilast 30 mg Oral Suspension - Fed |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Apremilast | 323 ± 34.5 | 274 ± 32.2 | 215 ± 33.7 |
Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay. AUC from time zero to the last measured time point was calculated by the linear trapezoidal method.
| ng*h/mL | Treatment A: Apremilast 30 mg Tablet - Fasted | Treatment B: Apremilast 30 mg Oral Suspension - Fasted | Treatment C: Apremilast 30 mg Oral Suspension - Fed |
|---|---|---|---|
| Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-t) for Apremilast | 3130 ± 38.9 | 2740 ± 43.1 | 3160 ± 41.3 |
Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay. AUC from time zero to infinity was calculated as (AUC0-t + Ct/λz), where Ct is the last quantifiable concentration, and λz is the apparent terminal rate constant.
| ng*h/mL | Treatment A: Apremilast 30 mg Tablet - Fasted | Treatment B: Apremilast 30 mg Oral Suspension - Fasted | Treatment C: Apremilast 30 mg Oral Suspension - Fed |
|---|---|---|---|
| Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-∞) for Apremilast | 3160 ± 38.7 | 2760 ± 43.2 | 3190 ± 41.3 |
Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.
| hours | Treatment A: Apremilast 30 mg Tablet - Fasted | Treatment B: Apremilast 30 mg Oral Suspension - Fasted | Treatment C: Apremilast 30 mg Oral Suspension - Fed |
|---|---|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast | 2.00 (1.00 to 5.00) | 2.00 (1.50 to 5.00) | 5.00 (1.50 to 12.00) |
| hours | Treatment A: Apremilast 30 mg Tablet - Fasted | Treatment B: Apremilast 30 mg Oral Suspension - Fasted | Treatment C: Apremilast 30 mg Oral Suspension - Fed |
|---|---|---|---|
| Terminal Elimination Half-life (T1/2) of Apremilast | 7.89 ± 34.5 | 8.51 ± 31.8 | 7.54 ± 30.8 |
| L/h | Treatment A: Apremilast 30 mg Tablet - Fasted | Treatment B: Apremilast 30 mg Oral Suspension - Fasted | Treatment C: Apremilast 30 mg Oral Suspension - Fed |
|---|---|---|---|
| Apparent Clearance of Apremilast From Plasma After Extravascular Administration (CL/F) | 9.51 ± 38.7 | 10.9 ± 43.2 | 9.42 ± 41.3 |
| L | Treatment A: Apremilast 30 mg Tablet - Fasted | Treatment B: Apremilast 30 mg Oral Suspension - Fasted | Treatment C: Apremilast 30 mg Oral Suspension - Fed |
|---|---|---|---|
| Apparent Volume of Distribution of Apremilast During the Terminal Phase (Vz/F) | 108 ± 45.2 | 133 ± 43.7 | 102 ± 38.9 |
Lag time is the delay between the time of administration and start of absorption.
| hours | Treatment A: Apremilast 30 mg Tablet - Fasted | Treatment B: Apremilast 30 mg Oral Suspension - Fasted | Treatment C: Apremilast 30 mg Oral Suspension - Fed |
|---|---|---|---|
| Lag Time (Tlag) of Apremilast | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
Relative bioavailability of the oral suspension formulation compared to the tablet formulation, calculated as (AUC0-∞/Dose\[oral suspension\]) / (AUC0-∞/Dose\[tablet\]) \* 100%.
| percent availability | Treatment B: Apremilast 30 mg Oral Suspension - Fasted | Treatment C: Apremilast 30 mg Oral Suspension - Fed |
|---|---|---|
| Relative Bioavailability (F) of Apremilast Oral Suspension Formulation | 87.6 ± 16.1 | 101 ± 14.3 |
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. A treatment-emergent AE (TEAE) was defined as any AE that occurred after dosing of the study drug. A serious adverse event (SAE) is any AE occurring at any dose that: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity; * Was a congenital anomaly/birth defect; * Constituted an important medical event.
| Participants | Treatment A: Apremilast 30 mg Tablet - Fasted | Treatment B: Apremilast 30 mg Oral Suspension - Fasted | Treatment C: Apremilast 30 mg Oral Suspension - Fed |
|---|---|---|---|
| Any treatment-emergent adverse event (TEAE) | 8 | 10 | 6 |
| TEAEs related to study drug | 4 | 7 | 4 |
| Serious adverse events | 0 | 0 | 0 |
| TEAEs leading to discontinuation | 0 | 0 | 0 |
| TEAEs leading to death | 0 | 0 | 0 |
Collected over From first dose of study drug in treatment period 1 to 8 days after the last dose; up to 18 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A: Apremilast 30 mg Tablet - Fasted | — | 0/34 (0%) | 5/34 (14.7%) |
| Treatment B: Apremilast 30 mg Oral Suspension - Fasted | — | 0/34 (0%) | 10/34 (29.4%) |
| Treatment C: Apremilast 30 mg Oral Suspension - Fed | — | 0/34 (0%) | 3/34 (8.8%) |
| Total | — | 0/34 (0%) | 15/34 (44.1%) |
| Event | Treatment A: Apremilast 30 mg Tablet - Fasted | Treatment B: Apremilast 30 mg Oral Suspension - Fasted | Treatment C: Apremilast 30 mg Oral Suspension - Fed | Total |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/34 | 5/34 | 1/34 | 5/34 |
| NauseaGastrointestinal disorders | 2/34 | 2/34 | 0/34 | 4/34 |
| HeadacheNervous system disorders | 2/34 | 2/34 | 2/34 | 4/34 |
| ConstipationGastrointestinal disorders | 0/34 | 2/34 | 1/34 | 3/34 |
| DyspepsiaGastrointestinal disorders | 1/34 | 1/34 | 0/34 | 2/34 |
| FlatulenceGastrointestinal disorders | 0/34 | 1/34 | 1/34 | 2/34 |
| Feeling hotGeneral disorders | 0/34 | 2/34 | 0/34 | 2/34 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 1/34 | 1/34 | 0/34 | 2/34 |
All randomized participants
| Age, Continuous(years) | Total |
|---|---|
| Mean | 33.3 (19 to 54) |
| Sex: Female, Male(Participants) | Total |
|---|---|
| Female | 9 |
| Male | 25 |
| Ethnicity (NIH/OMB)(Participants) | Total |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 33 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Total |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 1 |
| Black or African American | 14 |
| White | 17 |
| Other | 1 |
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
No publications or documents are linked to this record.
Ran from Jan 2016 to primary completion in Feb 2016, 1 month.
Results were first posted in Aug 2021, 5 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast